Oak vs Brand-Name GLP-1: Is the Habit-First Program Worth Switching For?

A friend of mine spent three weeks last winter arguing with her insurer about whether Wegovy counted as “medically necessary.” She lost. Then she found a telehealth program that mailed her a compounded shot for a third of the price and never asked her insurer anything. That gap — pharmacy-counter brand name versus mail-order compounded — is the whole reason people start reading up on Oak vs brand-name GLP-1 in the first place. Oak leans hard on habits and coaching around a compounded shot. Wegovy and Zepbound are the FDA-approved names your doctor already knows. They are not the same product, and they are not solving the same problem.

So let’s put them next to each other honestly. Not “which is better,” because that depends on you, but what you’re actually trading when you pick one.

Two different bets on how weight loss works

Brand-name GLP-1s treat the drug as the intervention. You take Wegovy (semaglutide) or Zepbound (tirzepatide), your appetite drops, and the clinical trials say the pounds follow. The support around it is thin by design — a prescriber, a pharmacy, maybe a portal. That’s fine if you already have your routines sorted and you just want the molecule.

Oak’s bet is different. It starts around $119 a month, ships compounded GLP-1 medication, and wraps free health coaching and a care team around the whole thing. The pitch, more or less: the shot quiets the hunger, but the coaching is what keeps the weight off after you eventually stop. Honestly, that framing only pays off if you actually use the coaching. If you ignore the check-ins and just want the injection, you’re paying for a program you’re not running.

Oak vs brand-name GLP-1: the numbers side by side

Prices below are 2026 cash-pay figures — what you hand over when insurance isn’t footing the bill, which for weight-loss drugs is still most people.

	Oak	Wegovy (self-pay)	Zepbound (self-pay)
Medication	Compounded GLP-1	Semaglutide, FDA-approved	Tirzepatide, FDA-approved
Starting monthly cost	From $119	$349 (injectable); oral pill $149–$299	$299 (2.5 mg vial), up to $449 higher doses
Coaching included	Yes, free	No	No
Insurance billing	No — cash program	Sometimes, if plan covers it	Sometimes, if plan covers it
How you get it	Online form, no video visit	Prescription + pharmacy	Prescription + pharmacy or LillyDirect
FDA status	Not an FDA-approved product	FDA-approved for weight loss	FDA-approved for weight loss

The dollar gap is real but narrower than it used to be. A year ago the brands wanted north of $1,000 a month at list. Now Novo Nordisk sells Wegovy direct at $349, and Lilly’s Zepbound vials start at $299. Oak’s roughly $119 starting point still undercuts them, and the coaching comes free rather than as an add-on. What you give up for that price is the FDA-approved label — and that’s not a small footnote.

The compounded-drug catch nobody should skip

Here’s the part the marketing pages tend to soft-pedal. Compounded semaglutide is not an FDA-approved drug. It was legal to make in bulk only while the FDA listed semaglutide as being in shortage, and that shortage was declared resolved back in February 2025. Routine compounding for general use wound down after that — 503A pharmacies had until late April 2025, outsourcing facilities a month more. Compounded GLP-1 can still reach you, but now a prescriber has to justify why the standard approved version won’t work for your specific case. So the decision genuinely sits with the clinician, not a checkout button.

None of that makes Oak’s model shady. Plenty of legitimate programs run this way. It just means the “compounded” line on the price sheet carries a different risk profile than a pharmacy-dispensed Wegovy pen, and you should know that going in. If your prescriber signs off, fine. If you’d rather have the drug the trials were actually run on, that’s the brand-name column.

Who Oak actually fits — and who should skip it

Oak makes sense if your insurance won’t touch a weight-loss drug, you’re paying out of pocket anyway, and you know yourself well enough to admit the medication alone won’t rebuild your eating habits. Roughly 42% of U.S. adults meet the clinical definition of obesity, and a big share of them have exactly that insurance problem. For that person, a $119 cash program with coaching baked in is a reasonable place to start.

Go brand-name instead if any of these are true: your plan covers Wegovy or Zepbound so your real cost is a copay, you’ve had a bad reaction before and want the exact studied formulation, or you’re simply not comfortable with a compounded product. The added coaching won’t matter much if you’ve already got your routine locked. We’d have liked to see Oak publish its full dose-by-dose pricing as plainly as Lilly now does — that’s the one place the brands are currently more transparent.

Frequently asked questions

Is Oak cheaper than Wegovy or Zepbound?

On sticker price, yes. Oak starts around $119 a month against roughly $299–$349 for the brands’ cash-pay routes, and Oak folds in coaching. But if your insurance covers a brand-name GLP-1, your copay could land below Oak’s cash price, so run your own coverage first.

Is compounded GLP-1 from Oak the same as brand-name semaglutide?

Same drug class and often the same active ingredient, but not the same product. Brand-name Wegovy and Zepbound are FDA-approved; compounded versions are not FDA-approved and are made by a compounding pharmacy under a prescriber’s direction. The clinical trial data belongs to the branded versions.

Do I need insurance to use Oak?

No. Oak runs as a cash-pay program and doesn’t bill insurance, which is part of why people with no GLP-1 coverage look at it. You complete an online health form, and a licensed provider reviews whether treatment is appropriate.

Which should I choose for long-term weight loss?

If you’ll genuinely lean on the habit coaching and you’re paying cash, Oak’s structure is built for the after-the-drug phase. If you want the FDA-approved medication and have coverage or prefer the studied formulation, the brand-name route is the safer pick. Talk it through with a prescriber either way.